Selective glycoimmuno-targeting for cancer therapy

Informations projet

SweetAim

N° de convention de subvention: 716220

DOI

10.3030/716220

Projet clôturé

Date de signature de la CE 28 Novembre 2016

Date de début 1 Decembre 2016

Date de fin 30 Novembre 2022

Financé au titre de

• EXCELLENT SCIENCE - European Research Council (ERC)

Coût total

€ 1 479 995,00

Contribution de l’UE

€ 1 479 995,00

Coordonné par

TEL AVIV UNIVERSITY
Israel

Periodic Reporting for period 4 - SweetAim (Selective glycoimmuno-targeting for cancer therapy)

Période du rapport: 2021-06-01 au 2022-11-30

Résumé du contexte et des objectifs généraux du projet

Cancer is a leading cause of death worldwide and new therapies are still needed. The primary objective of this proposal is to design a novel cancer therapeutic approach and to address the challenges faced by the study of carbohydrates immune recognition. It is based on findings that some tumor-associated carbohydrates can be targeted for cancer therapy. We investigated the potential of robust effective targeting of tumor-carbohydrates with antibodies both in vitro and in vivo. This research is has provided tools for designing novel therapeutics, imaging and diagnostics for cancer and for other chronic inflammation-related diseases, that are very important to reduce cancer burden for the benefit of society.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

We investigated carbohydrates as targets for antibody therapy in cancer. We explored the different factors that affect carbohydrate binding and recognition and developed several methods to improve antibody recognition and cancer killing potential both through passive therapy, as well as through active cancer vaccine design.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

We have already published fifteen papers and submitted 8 patents related to the use of antibodies for cancer diagnostics and therapy.

072120-nutri-red-meat-cancer-risk-low-resolution.jpg